7.965

1.21% 0.095

Leonabio Inc (LONA)

Overview News Price History Discussions Forecast

Leonabio Inc stock is traded at $7.965, with a volume of 9,289. It is up +1.21% in the last 24 hours and down -16.33% over the past month. LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

Previous Close:

$7.87

Open:

$7.86

24h Volume:

9,289

Relative Volume:

0.32

Market Cap:

$74.82M

Revenue:

Net Income/Loss:

$-129.41M

P/E Ratio:

-0.3306

EPS:

-24.0922

Net Cash Flow:

$-51.97M

1W Performance:

+3.71%

1M Performance:

-16.33%

6M Performance:

+83.53%

1Y Performance:

+0.00%

1-Day Range:

$7.715

$8.275

1-Week Range:

$7.33

$8.275

52-Week Range:

$4.21

$14.21

Leonabio Inc Stock (LONA) Company Profile

Name

Leonabio Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(425) 620-8501

Address

18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

LONA's Discussions on Twitter

Compare LONA vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LONA Leonabio Inc	7.965	73.93M	0	-129.41M	-51.97M	-24.09
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Leonabio Inc Stock (LONA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-26	Initiated	Cantor Fitzgerald	Overweight
Feb-19-26	Upgrade	Mizuho	Neutral → Outperform
Sep-19-24	Downgrade	Mizuho	Outperform → Neutral
Sep-04-24	Downgrade	BTIG Research	Buy → Neutral
Sep-04-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Sep-04-24	Downgrade	Rodman & Renshaw	Buy → Neutral
Aug-19-24	Initiated	Rodman & Renshaw	Buy
Oct-17-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Jul-07-22	Initiated	Mizuho	Buy
Jun-23-22	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-23-22	Downgrade	Jefferies	Buy → Hold
Jun-23-22	Downgrade	Stifel	Buy → Hold
May-10-22	Initiated	BTIG Research	Buy
Apr-21-22	Initiated	Berenberg	Buy
Dec-15-21	Initiated	Goldman	Neutral
Oct-13-20	Initiated	Goldman	Buy
Oct-13-20	Initiated	JMP Securities	Mkt Outperform
Oct-13-20	Initiated	Jefferies	Buy
Oct-13-20	Initiated	Stifel	Buy

View All

Leonabio Inc Stock (LONA) Latest News

Aug 14, 2026

LeonaBio Q2 Results: EPS beats estimate, losses narrow 55% YoY - scanx.trade

Aug 14, 2026

LeonaBio Narrows Q2 Loss - marketscreener.com

Aug 14, 2026

LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times

Aug 14, 2026

LeonaBio (LONA) loss widens as cash burn rises and going concern risk emerges - Stock Titan

Aug 14, 2026

LeonaBio Q2 net loss widens on higher R&D spending - TradingView

Aug 14, 2026

LeonaBio Posts $19.0 Million Q2 Loss as ELAINE-3 Enrollment Advances - Quiver Quantitative

Aug 14, 2026

LeonaBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 14, 2026

Aug 13, 2026

LeonaBio, Inc. (NASDAQ: LONA) Share Price, LONA Stock News, LONA Share Price & Updates - kalkine.ca

Aug 13, 2026

Aug 12, 2026

LeonaBio’s lasofoxifene to be featured at breast cancer summit By Investing.com - Investing.com Nigeria

Aug 12, 2026

LeonaBio’s lasofoxifene to be featured at breast cancer summit - Investing.com

Aug 12, 2026

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology’s 4th Summit on Breast Cancer - The Manila Times

Aug 12, 2026

LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), - GlobeNewswire

Aug 12, 2026

Aug 09, 2026

LONA: LeonaBio, Inc.12 Month EPS - Zacks Investment Research

Aug 09, 2026

Aug 03, 2026

LeonaBio Inc expected to post a loss of $1.26 a shareEarnings Preview - TradingView

Aug 03, 2026

Jul 30, 2026

Citizens upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com Canada

Jul 30, 2026

Jul 29, 2026